Cargando…

A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles

Tuberculosis (TB) is one of the top 10 causes of death worldwide. This scenario is further complicated by the insurgence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. The identification of appropriate drugs with multi-target affinity profiles is considered to be a widely acce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Battah, Basem, Chemi, Giulia, Butini, Stefania, Campiani, Giuseppe, Brogi, Simone, Delogu, Giovanni, Gemma, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930672/ https://www.ncbi.nlm.nih.gov/pubmed/31795400 http://dx.doi.org/10.3390/molecules24234373

Ejemplares similares

Computational Tool for Fast in silico Evaluation of hERG K(+) Channel Affinity
por: Chemi, Giulia, et al.
Publicado: (2017)

Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
por: Sirous, Hajar, et al.
Publicado: (2019)

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases
por: Maramai, Samuele, et al.
Publicado: (2016)

Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases
por: Brogi, Simone, et al.
Publicado: (2022)

Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors
por: Sirous, Hajar, et al.
Publicado: (2020)

Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
por: Flori, Lorenzo, et al.
Publicado: (2023)

The green chemistry of chalcones: Valuable sources of privileged core structures for drug discovery
por: Marotta, Ludovica, et al.
Publicado: (2022)

In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors
por: Brogi, Simone, et al.
Publicado: (2016)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Development of Quinazolinone Derivatives as Modulators of Virulence Factors of Pseudomonas aeruginosa Cystic Fibrosis Strains
por: Carullo, Gabriele, et al.
Publicado: (2023)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Accelerating the repurposing of FDA-approved drugs against coronavirus disease-19 (COVID-19)
por: De Vita, Simona, et al.
Publicado: (2020)

Crystal structures of Schistosoma mansoni histone deacetylase 8 reveal a novel binding site for allosteric inhibitors
por: Saccoccia, Fulvio, et al.
Publicado: (2022)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
por: Fontana, Anna, et al.
Publicado: (2022)

Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
por: Kulkarni, Ameya S., et al.
Publicado: (2022)

Repurposing FDA-approved drugs as FXR agonists: a structure based in silico pharmacological study
por: Jose, Sandra, et al.
Publicado: (2023)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking
por: Brindisi, Margherita, et al.
Publicado: (2015)

Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
por: O’Reilly, Paul G., et al.
Publicado: (2016)

Computational Cell Cycle Profiling of Cancer Cells for Prioritizing FDA-Approved Drugs with Repurposing Potential
por: Lo, Yu-Chen, et al.
Publicado: (2017)

Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease
por: Cannon, Matthew, et al.
Publicado: (2020)

FDA Approved Drugs Repurposing of Toll-Like Receptor4 (TLR4) Candidate for Neuropathy
por: Zali, Hakimeh, et al.
Publicado: (2019)

Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats
por: Zulfiqar, Zikra, et al.
Publicado: (2020)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Design and Synthesis of Oligopeptidic Parvulin Inhibitors
por: Relitti, Nicola, et al.
Publicado: (2022)

Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
por: Papa, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lqr9karo5skt9mvnum80vuaeha